Skip to main content

Table 2 The univariate analysis for IPSS increment. The univariate analysis of wheather t-IPSS increased by ten or over ten points during 91–180 days after ISBT. Similary, o-IPSS and i-IPSS increment of five or over five points during the same time period was analyzed

From: After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer

p value
Factor   t-IPSS+10 o-IPSS+5 i-IPSS+5
Age <66.17 vs >66.17 0.838 0.959 0.253
Prostate volume <36.7 ml vs >36.7 ml 0.681 0.457 0.750
Risk group intermediate vs high 0.820 0.540 0.318
Initial PSA <11.84 vs >11.84 1.000 0.609 0.124
Baseline t-IPSS <7.67 vs >7.67 0.217 0.400 0.253
ADT yes vs no 1.000 0.505 0.472
Brachytherapy technique LDR-ISBT vs HDR-ISBT 0.066 0.193 0.010*
D50 % of urethra <95.65 Gy vs >95.65 Gy 0.024* 0.101 0.031*
D50 % of base of urethra <95.70 Gy vs >95.70 Gy 0.152 0.397 0.031*
V90 of urethra <85.32 % vs >85.32 % 0.152 0.397 0.031*
V90 of base of urethra <75.01 % vs >75.01 % 0.152 0.397 0.031*
V100 of urethra <17.05 % vs >17.05 % 0.217 0.535 0.005*
  1. Abbreviations: ADT androgen deprivation therapy, IPSS international Prostate Symptom Score, t-IPSS total score of IPSS, o-IPSS + 5 total score of IPSS about obstructive symptom, i-IPSS + 5 total score of IPSS about irritative symptom, Dx% minimum dose delivered to x% of the organ volume, Vx proportion of volume receiving x Gy. The Gy indicates the dose which was converted into the EQD2
  2. The * indicates a variable that has a significant difference